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ABSTRACT 
Introduction: There has been increased attention 
on the potential impact of the preservative 
benzalkonium chloride (BAK) on the ocular 
surface. This study compared the ocular surface 
tolerability of once-daily bimatoprost 0.01% 
and latanoprost 0.005% (both preserved with 
0.02% BAK), and travoprost 0.004% preserved 
with sofZiaTM.
Methods: A randomized, multicenter (15 sites), 
investigator-masked study enrolled patients with 
open-angle glaucoma or ocular hypertension who 
had received latanoprost monotherapy for at least 
1 month. Patients were randomized to once-
daily bimatoprost (n = 56), travoprost (n = 53), or 
latanoprost (n = 55) monotherapy for 3 months. 
Follow-up visits were at weeks 1, 4, and 12. The 
primary outcome measure was physician-graded 
conjunctival hyperemia (scale 0 to 3) at week 12. 
Secondary outcomes included corneal staining 
(scale 0 to 3) and tear break-up time (TBUT).
Results: There were no significant differences 
in mean (s tandard deviat ion [SD]) 
outcome measures including conjunctival 
hyperemia (bimatoprost:  0.48 [0.52], 
travoprost: 0.49 [0.52], latanoprost: 0.51 [0.54]), 
corneal staining (bimatoprost: 0.31 [0.49], 
travoprost: 0.25 [0.46], latanoprost: 0.24 [0.45]), or 
TBUT (bimatoprost: 9.7 s [6.1], travoprost: 9.5 s [5.8], 
latanoprost: 9.8 s [5.0]) among subjects at 
latanoprost-treated baseline (P ≥ 0.664). At 
week 12, there were no significant differences 
in conjunctival hyperemia (bimatoprost: 
0.42 [0.48],  travoprost:  0.46 [0.44], 
latanoprost: 0.44 [0.57]), corneal staining 
(bimatoprost: 0.31 [0.45], travoprost: 0.32 [0.48], 
latanoprost: 0.22 [0.30]), or TBUT (bimatoprost: 
9.7 s [5.7], travoprost 9.7 s [5.0], latanoprost: 9.3 s [4.0]) 
among the treatment groups (P ≥ 0.379). At week 1, 
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active agent; for example, bimatoprost 0.03% 
(Lumigan®; Allergan, Inc., Irvine, CA, USA) is 
preserved with 0.005% BAK and latanoprost 
0.005% (Xalatan®; Pfizer Inc, New York, NY, 
USA) with 0.02% BAK. Other preservatives 
have recently been employed; in particular, 
the proprietary system sofZiaTM used in the 
formulation of travoprost 0.004% ophthalmic 
solution (Travatan Z®; Alcon Laboratories, 
Inc., Fort Worth, TX, USA). In a recent clinical 
study, no statistically significant among-
group differences were seen in patients after 
3 months of use of once-daily bimatoprost 
0.03% (preserved with 0.005% BAK), latanoprost 
(preserved with 0.02% BAK), and travoprost 
(preserved with sofZia) in objective measures 
of ocular surface tolerability, including 
conjunctival hyperemia, corneal staining, and 
tear break-up time (TBUT) [12].
While corneal toxicity secondary to BAK 
has been shown in prior in vitro and rabbit 
studies [13], it is unclear whether these studies 
accurately replicate ocular surface conditions 
in patients undergoing treatment with IOP-
lowering medications preserved with BAK. 
Exposure to BAK in some of these studies 
exceeds that experienced by many patients 
administering topical medications preserved 
with BAK. 
Recently, a new formulation of bimatoprost 
0.01% preserved with 0.02% BAK was approved. 
This formulation was designed to maintain the 
IOP-lowering efficacy of bimatoprost 0.03% 
and to provide an improved ocular surface 
tolerability profile. The present 12-week study 
was undertaken to examine the ocular surface 
tolerability of once-daily bimatoprost 0.01% 
and latanoprost (both preserved with 0.02% 
BAK), and travoprost 0.004% (preserved with 
sofZia) in adult patients with glaucoma or 
ocular hypertension following a run-in on 
latanoprost. 
there was a statistically significant among-group 
difference in mean change from baseline in 
hyperemia (+0.04, bimatoprost; +0.20, travoprost; 
0.00, latanoprost; P = 0.018). There were no 
statistically significant among-group differences 
in mean corneal staining, mean TBUT, or change 
from baseline at any visit.
Conclusions: Despite preservative differences, 
there were no significant differences in objective 
clinical measures of ocular surface tolerability 
after 3 months of treatment with bimatoprost 
(with 0.02% BAK), travoprost (with sofZia), and 
latanoprost (with 0.02% BAK).
Keywords :  Benza lkon ium ch lo r ide ; 
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INTRODUCTION
The prostaglandin analogs and prostamides [1, 2] 
are commonly prescribed first-line medications 
for glaucoma or ocular hypertension based 
upon their efficacy in lowering intraocular 
pressure (IOP), favorable safety and tolerability 
profiles, and ease of once-daily dosing [3–5]. 
The most frequently reported side effect of these 
medications, conjunctival hyperemia, is often 
transient and not associated with inflammation 
or other negative sequelae [4, 6, 7]. 
Prostaglandin analogs (travoprost and 
latanoprost) and prostamides (bimatoprost) are 
typically administered from multidose bottles 
that contain preservatives to ensure sterility. 
Benzalkonium chloride (BAK) is the most 
commonly used preservative in ophthalmic 
medications as a result of its broad-spectrum 
bactericidal and bacteriostatic activity at 
physiological pH [8–11]. The concentration 
of BAK in ophthalmic formulations varies 
over several fold, depending on the particular 
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with administration of latanoprost monotherapy. 
At the baseline visit (day 0) patients discontinued 
latanoprost monotherapy and were randomized 
in a 1:1:1 ratio to three treatment groups: 1) 
bimatoprost 0.01% preserved with 0.02% BAK 
(Lumigan® 0.01%; Lumigan® RC; Allergan, Inc., 
Irvine, CA); 2) travoprost 0.004% preserved with 
sofZia (Travatan Z®; Alcon Laboratories, Inc., Fort 
Worth, TX); and 3) latanoprost 0.005% preserved 
with 0.02% BAK (Xalatan®; Pfizer Inc, New York, 
NY). In this investigator-masked study, study 
medications (Lumigan® 0.01%/Lumigan® RC, 
Travatan Z®, and Xalatan®) were over-labeled 
and packaged into kits according to treatment 
groups A, B, and C, and made available for 
dispensing at the baseline visit (visit 2, day 0) 
and week 4 visit according to the randomization 
schedule. Masked study drugs were administered 
once daily as a single drop in each eye between 
7:00 and 9:00 pm for 12 weeks.
Assessments and Outcomes Variables 
Study visits were scheduled at consistent times in 
the morning, at baseline, and weeks 1, 4, and 12. 
At each study visit, ocular tolerability and safety 
assessments were conducted. The primary 
outcome measure was bulbar conjunctival 
hyperemia at week 12. Observations were 
graded by a comparison with color photographic 
standards employing the following values: 
0 = none (normal); 0.5 = trace (trace flush, 
reddish pink); 1 = mild (mild flush, reddish 
color); 2 = moderate (bright red color); and 
3 = severe (deep, bright diffuse redness). 
Secondary outcome measures included corneal 
staining with fluorescein and TBUT using the slit 
lamp at 10× magnification. Corneal staining of 
superficial punctate keratopathy was graded on 
a scale of 0 = none (no findings), 0.5 = trace (1–5 
puncta), 1 = mild (6–20 puncta), 2 = moderate 
(>20 puncta), and 3 = severe (too many puncta 
MATERIALS AND METHODS
Study Design and Patient Disposition
This was a 3-month, multicenter, randomized, 
investigator-masked, parallel-group comparison 
study conducted at 15 sites in the United 
States and Canada. The study was approved 
by the respective institutional review boards 
or independent ethics committees at each site 
and followed the regulations of the Health 
Insurance Portability and Accountability Act 
and the Good Clinical Practice guidelines of 
the Declaration of Helsinki. Written informed 
consent was obtained from all subjects or their 
legally authorized representatives. 
Eligible patients were ≥18 years of age, with 
best-corrected Snellen visual acuity of ≥20/100 in 
both eyes, and diagnosis of ocular hypertension 
or chronic open-angle glaucoma, requiring 
antiglaucoma/ocular hypotensive agents. Key 
exclusion criteria were the use of bimatoprost or 
travoprost within the past 6 months, any corneal 
abnormalities (scar, edema, or keratoconus) 
preventing assessments of IOP, a history of 
refractive surgery or punctal plug use, a history 
of active ocular infection or inflammation, 
need for ocular medications other than the 
study treatments (intermittent use of BAK-free 
artificial tears was permitted), known sensitivity 
or allergy to study medications, any systemic 
disease that could confound study results, or in 
the opinion of the investigator, made the patient 
unsuitable for the study. 
Newly diagnosed patients underwent a 
30-day run-in on latanoprost 0.005% (Xalatan®; 
Pfizer Inc, New York, NY, USA) monotherapy, 
while those who had been receiving latanoprost 
monotherapy continued treatment. Patients 
who were receiving combination or alternate 
medications at screening underwent a 30-day 
washout of all other medications, concomitant 
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to count). Biomicroscopy was performed by 
the investigator (or designee) by slit lamp 
examination without pupil dilation. 
Sa fe ty  a s se s sments  inc luded  IOP 
measurements and adverse events. All IOP 
measurements were made once per visit before 
12:00 pm as per protocol. Adverse events were 
recorded, with an assessment of severity (graded 
as mild, moderate, or severe), action taken, and 
relationship to study medication (graded as 
definite, probable, and not related).
Statistical Analyses
For purpose of analysis, the intent-to-treat (ITT) 
population included all subjects who were 
randomized to study medication. The per-protocol 
(PP) population, a subset of the ITT population, 
included all subjects who completed 12 weeks of 
treatment without significant protocol violations. 
The safety population included all subjects who 
were exposed to study medication. 
Differences in outcomes among the treatment 
groups were analyzed using analysis of variance 
(ANOVA) for the among-group differences, using 
the ITT population, and last observation carried 
forward for missing values. In the analysis 
of conjunctival hyperemia, corneal staining, 
and TBUT, analyses were performed using the 
average value of both eyes. If the overall null 
hypothesis was rejected, pairwise comparisons 
were made using the two-sample t-test using 
the PP population. Change from baseline was 
summarized and analyzed similarly, including 
the use of a paired t-test for change within a 
treatment group. In addition, all biomicroscopy 
changes were summarized for change from 
baseline at week 12, and categorized as “no 
change,” “decrease ≥0.5,” “increase = 0.5,” 
“increase >0.5,” and “increase ≥1.” The analysis 
was performed using the ITT population and no 
hypothesis testing was performed. 
Safety data were summarized for the safety 
population. For adverse events, among-group 
differences were analyzed using a two-tailed 
Fisher’s exact test. IOP was averaged over both 
eyes for analysis, and the results at baseline and 
each follow-up visit were analyzed by ANOVA. 
Change from baseline in IOP was summarized at 
each follow-up visit using analysis of covariance 
with effects for treatment group and baseline 
IOP, while within-group change was analyzed 
using a paired t-test. All observed safety data 
were analyzed and there was no imputation for 
missing values.
A sample size of 49 subjects per treatment 
group provided: 1) 99% power to detect 
an among-group difference for all three 
treatment groups and 2) 95% power to detect a 
0.5 score difference in any pairwise comparison 
of conjunctival hyperemia. The significance level 
was set at 0.05 for each of these calculations based 
on the condition that pairwise comparisons are 
only to be performed if the overall among-group 
test is statistically significant. 
RESULTS
Patient Disposition
In total, 164 patients (both ITT and safety 
population) were randomized to the three 
treatment groups (Table 1) and received study 
medication; the PP population comprised 
150 patients. There were no significant 
differences among treatment groups in 
patient demographics or ocular diagnoses at 
baseline (Table 1). Treatment history of study 
population reveals that 68.9% had more 
than 1 year of treatment, 50.0% had at least 
3 years, and 14.0% had more than 10 years 
of treatment with IOP-lowering medications. 
Eleven patients discontinued treatment before 
week 12 (Table 2). 
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Table 1  Baseline characteristics of all enrolled patients
Safety population Bimatoprost 0.01%
(n = 56)
Travoprost 0.004% with sof Zia
(n = 53) 
Latanoprost 0.005%
(n = 55)
Mean age (SD), years* 65.1 (11.76) 63.2 (13.57) 64.7 (12.28)
Gender, male, n (%)** 20 (35.7) 28 (52.8) 24 (43.6)
Race/ethnicity, n (%)***
Caucasian 31 (55.4) 32 (60.4) 30 (54.5)
Black 10 (17.9) 9 (17.0) 11 (20.0)
Hispanic 10 (17.9) 8 (15.1) 10 (18.2)
Asian 2 (3.6) 3 (5.7) 3 (5.5)
Other 3 (5.4) 1 (1.9) 1 (1.8)
Diagnosis, n (%)****
OAG 37 (66.1) 35 (66.0) 33 (60.0)
OHT 10 (17.9) 10 (18.9) 12 (21.8)
Other 9 (16.1) 8 (15.1) 10 (18.2)
Treatment history, n (%)a
<1 year 5 (8.9) 9 (17.0) 10 (18.2)
1–3 years 11 (19.6) 8 (15.1) 12 (21.8)
3–5 years 10 (17.9) 10 (18.9) 9 (16.4)
5–10 years 7 (12.5) 12 (22.6) 11 (20.0)
>10 years 12 (21.4) 6 (11.3) 5 (9.1)
No medication at screening 11 (19.6) 8 (15.1) 8 (14.5)
Medication at screening, n (%)
PGA/PM only 37 (66.1) 38 (71.7) 43 (78.2) 
BB only 2 (3.6) 3 (5.7) 0 
PGA/PM+BB FC 1 (1.8) 1 (1.9) 1 (1.8) 
Other 
BB+PGA/PM 2 (3.6) 2 (3.8) 3 (5.5) 
BB+CAI 1 (1.8) 0 0 
PGA/PM+CAI 0 1 (1.9) 0 
PGA/PM+FC product 2 (3.6) 0 0 
BB beta blocker, CAI carbonic anhydrase inhibitor, FC xed combination, OAG open-angle glaucoma, OHT ocular 
hypertension, PGA prostaglandin analog, PM prostamide, SD standard deviation 
* P = 0.707 based on two-sample t test; ** P = 0.205; *** P = 0.833 both based on Fisher’s exact test; **** P = 0.993
a Duration of one or more IOP-lowering medications before baseline
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Ocular Surface Tolerability
Hyperemia
There were no significant differences in 
conjunctival hyperemia scores among groups 
at latanoprost-treated baseline. At 12 weeks 
(primary endpoint), the mean (standard 
deviation [SD]) conjunctival hyperemia score 
was 0.42 (0.48) for bimatoprost, 0.46 (0.44) 
for travoprost, and 0.44 (0.57) for latanoprost 
(P = 0.907). Statistically significant among-
group differences were seen in change from 
baseline in conjunctival hyperemia at 1 week 
(0.04 [0.34] for bimatoprost, 0.20 [0.39] for 
travoprost, and 0.00 [0.42] for latanoprost; 
P = 0.018; Fig. 1). Pairwise t-tests were significant 
for travoprost versus both bimatoprost 
(P = 0.034) and latanoprost (P = 0.007), but not 
for bimatoprost versus latanoprost (P = 0.542). 
Changes within groups were not significant 
at any visit for each of the bimatoprost and 
the latanoprost groups; however, with the 
travoprost group, change from baseline was 
significant at weeks 1 and 4, where the mean 
change (SD) in hyperemia was an increase of 
0.20 (0.39) at week 1 (P < 0.001) and an increase 
of 0.13 (0.47) at week 4 (P = 0.046). 
Corneal Staining
There were no significant among-group 
differences in mean corneal staining at baseline 
or mean staining at any visit (P ≥ 0.379; Fig. 2). 
At baseline, the mean (SD) corneal staining score 
was 0.31 (0.49) in the bimatoprost group, 0.25 
(0.46) in the travoprost group, and 0.24 (0.45) in 
the latanoprost group (P = 0.664). At 12 weeks, 
the mean (SD) score was 0.31 (0.45) in the 
bimatoprost group, 0.32 (0.48) in the travoprost 
group, and 0.22 (0.30) in the latanoprost group 
(P = 0.379). Moreover, there were no significant 
among-group differences in the change from 
baseline corneal staining scores at weeks 1, 4, 
and 12 (P ≥ 0.237). At week 12, the mean (SD) 
Table 2  Reasons for discontinuation
n (%) Bimatoprost 0.01% 
(n = 56) 
Travoprost 0.004% with sof Zia  
(n = 53) 
Latanoprost 0.005%
(n = 55)
Patient decision 1 (1.8) 0 2 (3.6)
Investigator decision 1 (1.8) 0 0
Lost to follow-up 1 (1.8) 1 (1.9) 0
Adverse event 1 (1.8) 0 2 (3.6)
Other 1 (1.8) 1 (1.9) 0
Patient/investigator decision – patient/investigator decides it is best interest to be withdrawn
Adverse event – branch retina artery occlusion, le eye (bimatoprost); aspiration pneumonia resulting in death, punctured 
colon (latanoprost)






















Baseline Week 1 Week 4 Week 12




Fig. 1  Mean hyperemia score at each visit (intent-to-treat 
population)
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change from baseline corneal staining scores 
was 0.00 (0.44) in the bimatoprost group, 0.08 
(0.50) in the travoprost group, and –0.02 (0.51) 
in the latanoprost group (P = 0.535). There were 
no significant changes from baseline within any 
of the treatment groups.
Tear Break-up Time
As with corneal staining, there were no 
statistically significant among-group differences 
in mean TBUT times at baseline or at any visit. 
Mean (SD) TBUT at baseline was 9.7 s (6.14) 
in the bimatoprost group, 9.5 s (5.77) in 
the travoprost group, and 9.8 s (5.00) in the 
latanoprost group (P = 0.951). At 12 weeks, 
the TBUT was 9.7 s (5.71) in the bimatoprost 
group, 9.7 s (4.96) in the travoprost group, 
and 9.3 s (4.04; P = 0.871) in the latanoprost 
group. There were no significant differences 
among the treatment groups in mean TBUT 
at any follow-up visit (P ≥ 0.847; Fig. 3). 
Similarly, there were no significant among-
group differences in the change from baseline 
at any visit (P ≥ 0.630). At week 12, the mean 
(SD) changes from baseline TBUT were 0.0 s 
(4.47), 0.2 s (4.65), and –0.5 s (2.92) in the 
bimatoprost, travoprost, and latanoprost 
groups, respectively. Moreover, there were no 
significant within-group changes from baseline 
for any of the three treatment groups.
Biomicroscopy
Overall, there was either no change or a decrease 
in conjunctival hyperemia from baseline in 
88.2% of bimatoprost-treated patients, 70.6% 
of travoprost-treated patients, and 84.6% 
of latanoprost-treated patients at week 12. 
A ≥1-unit increase in conjunctival hyperemia 
from baseline at week 12 was observed in 2.0% 
of the bimatoprost group, 5.9% of the travoprost 
group, and 3.8% of the latanoprost group (Fig. 4). 
There was either no change or a decrease in 
corneal staining in 76.5% of the bimatoprost 
group, 70.6% in the travoprost group, and 67.3% 
in the latanoprost group. A ≥1-unit increase in 
corneal staining was observed in 2.0% of the 
bimatoprost group, 5.9% of the travoprost group, 
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Fig. 4  Biomicroscopy ndings. Incidence of ≥1-unit 
increase in the severity of biomicroscopy ndings from 
baseline to week 12 (intent-to-treat population)
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Safety
Intraocular Pressure
Intraocular pressure was not significantly 
different among the three groups at latanoprost-
treated baseline (P = 0.232). There were no 
significant among-group differences in change 
from baseline at any follow-up visit (P ≥ 0.236; 
Table 3). Bimatoprost demonstrated a statistically 
significant reduction in IOP from latanoprost-
treated baseline at every follow-up visit (weeks 1, 
4, and 12), ranging from mean (SD) reductions of 
0.8 (2.67) mmHg at week 1 to 1.0 (3.01) mmHg 
at week 4, and 1.0 (2.84) mmHg at week 12 
(P ≤ 0.039; Table 3). There were no statistically 
significant reductions from latanoprost-treated 
baseline in the travoprost group at either week 1 
(0.7 [2.56] mmHg [P = 0.056]) or week 4 
(0.5 [2.55] mmHg [P = 0.138]). The change in 
IOP was significant only at week 12 for the 
travoprost group (1.0 [2.10] mmHg [P = 0.001]). 
There were no statistically significant changes 
in IOP from baseline following randomization 
in the latanoprost-treated group at any visit 
(P ≥ 0.239).
Adverse Events
All three treatments were well tolerated and 
adverse event incidence rates were comparable 
among groups (Table 4). The treatment-related 
ocular adverse events included two cases of 
itchy lids in the bimatoprost group, two cases 
of hyperemia and two cases of dryness in the 
travoprost group, and one case of ocular itching 
in the latanoprost group. No treatment-related 
serious adverse events were reported. 
DISCUSSION
This study evaluated two prostaglandin analogs 
and a prostamide that differed in active agents 
and type of preservative. At 3 months, there 
were no significant differences among the study 
medications in objective clinical measures of ocular 
surface tolerability, including hyperemia, corneal 
staining, or TBUT, despite differences in type of 
preservative. Interestingly, among-group differences 
were seen in change from baseline to week 1 in 
conjunctival hyperemia (P = 0.018). While there 
were no statistically significant changes from 
the latanoprost-treated baseline in conjunctival 
hyperemia in the bimatoprost- or latanoprost-
treated eyes at any visit, there was a statistically 
significant increase in hyperemia from latanoprost-
treated baseline in the travoprost-treated eyes at 
both weeks 1 (P < 0.001) and 4 (P = 0.046).
Corneal staining and TBUT were not statistically 
significantly different among the groups at 
Table 3  Within-group intraocular pressure changes from baseline in the safety population
Bimatoprost 0.01%  
(n = 56)
Travoprost 0.004% with sof Zia 
(n = 53)
Latanoprost 0.005%  
(n = 55)
Baseline 16.8 16.4 15.6
Week 1 –0.8 –0.7 –0.4
P value 0.039 0.056 0.239
Week 4 –1.0 –0.5 –0.4
P value 0.023 0.138 0.250
Week 12 –1.0 –1.0 –0.1
P value 0.022 0.001 0.778
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that BAK may have a deleterious impact on 
the ocular surface, it is unclear whether these 
findings are clinically relevant. In at least 
some of these reports, BAK exposure is much 
greater than that experienced clinically [13]. 
Differences in ocular physiology between 
rabbits and humans, including the presence of 
a nictitating membrane [15] and differences in 
blink rate [16, 17], may account for some of the 
difference in findings between those preclinical 
studies and the present study. The present study 
demonstrates that over 3 months, there was 
no observable clinical impact on ocular surface 
tolerability parameters despite differences in 
preservatives and active agents. 
In the present study, all patients were run 
in on latanoprost monotherapy for 30 days 
prior to baseline, which may impact tolerability 
results relative to patients naïve to IOP-lowering 
therapy. An additional limitation of this study 
was the duration of 3 months. Long-term studies 
that evaluate tolerability in patients receiving 
multiple topical medications and in patients 
with severe ocular surface disease are warranted.
CONCLUSION
Patients with glaucoma and ocular hypertension 
had comparable ocular tolerability findings with 
latanoprost-treated baseline or at any follow-up 
visit. In addition, among-group differences in the 
change from baseline in these parameters were 
also not significant at any follow-up visit, nor were 
the changes from baseline within any of the three 
treatment groups. 
This study was intended to assess the 
typical glaucoma patient population and did 
not exclude patients who may have had dry 
eye symptoms at baseline. The majority of 
patients (64%) were diagnosed with glaucoma 
and most patients had been treated previously 
with IOP-lowering medications, with at least 
50% of patients having received treatment 
for ≥3 years (Table 1). Patients with punctal 
plugs were excluded to ensure that there were 
no differences in residence times of study 
medications on the ocular surface. The findings 
are in accord with an earlier report [12] using a 
similar protocol to compare bimatoprost, used 
at a higher concentration (0.03%), travoprost, 
and latanoprost. The findings are also consistent 
with the analysis by Schwartz et al. of medical 
and pharmacy claims databases in which new 
patients initiated on latanoprost with BAK and 
travoprost with sofZia had similar rates of dry 
eye and ocular surface disease at 1 year [14]. 
While many preclinical studies using both 
in vitro and in vivo models have suggested 
Table 4  Adverse events
Safety population Bimatoprost 0.01%  
(n = 56)
Travoprost 0.004% with sof Zia 
(n = 53)
Latanoprost 0.005%  
(n = 55)
No. of patients with AE* 6 5 5
Ocular** 4 3 2
Treatment-related ocular 2 3 1
No. of patients with SAEa 1 1 3
AE adverse event, SAE serious adverse event
* P > 0.999 (Fisher’s exact test); ** P = 0.771 (Fisher’s exact test)
a All SAEs were unrelated to treatment
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respect to objective measures of conjunctival 
hyperemia, corneal staining, and TBUT 
following 12 weeks of treatment. Differences in 
type of preservative (i.e., BAK vs. sofZia) did not 
lead to observable clinical differences in ocular 
surface tolerability at 3 months. Adverse event 
incidence rates were comparable among groups. 
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